去纤苷能完全治好肝小静脉闭塞症吗？

Defibrotide is an effective drug for the treatment of hepatic veno-occlusive disease, but it does not completely cure hepatic veno-occlusive disease.

Although defibrotide can improve microcirculation and thereby improve hepatic veno-occlusive disease, it cannot directly repair damaged liver cells or improve the structure of the liver. Therefore, hepatic veno-occlusive disease requires comprehensive consideration of the patient's specific conditions and comprehensive treatment under the guidance of a doctor.

Defibrinoside

It is approved in the EU for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinus tract obstruction syndrome, in hematopoietic stem cell transplantation (HSCT) therapy, and is suitable for adults, adolescents, children and infants over 1 month old.

Why defibrotide cannot completely cure hepatic veno-occlusive disease

Defibrinoside is an effective drug for the treatment of hepatic veno-occlusive disease (VOD). It is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. It can inhibit platelet aggregation, reduce blood viscosity, improve microcirculation, and thus has a therapeutic effect on hepatic veno-occlusive disease.

In vitro evidence suggests that defibrotide can restore the thrombo-fibrinolytic balance at the endothelial level and protect endothelial cells. Defibrotide has been shown to significantly reduce VOD/SOS-related mortality and resolve VOD/SOS-related symptoms with a manageable safety profile.

It should be noted that defibrotide cannot directly repair damaged liver cells or improve the structure of the liver. Therefore, it cannot completely cure hepatic veno-occlusive disease. Comprehensive treatment still needs to be carried out taking into account the specific situation of the patient. Hepatic sinusoidal obstruction syndrome/hepatic veno-occlusive disease is a serious disease, and its treatment is difficult. There is currently no specific treatment method. If it can be detected early and active treatment measures can be taken, the progression of the disease may be slowed down and the patient's symptoms and quality of life can be improved.

What is hepatic veno-occlusive disease

Hepatic veno-occlusive disease (VOD) is intrahepatic retrosinusoidal portal hypertension caused by stenosis or occlusion of the central and sublobular veins of the liver for some reason. It can also be called hepatic sinusoidal obstruction syndrome. It is an early complication after hematopoietic stem cell transplantation (HSCT). The main manifestations are hepatomegaly, jaundice, and ascites. Mild patients can recover, but severe patients mostly die of multiple organ failure, and a few develop cirrhosis.

Defibrotide in the treatment of hepatic veno-occlusive disease

In three clinical studies, eligible children or adults with hepatic veno-occlusive disease were enrolled and received defibrotide treatment. The efficacy of defibrotide is based on +100-day survival after HSCT. In Study 1, survival at 100 days after transplantation was 38%, in Study 2, survival was 44%, and in Study 3, survival at Day +100 was 45%.

Medication

1. Bleeding: During medication, inform patients that defibrotide may increase the risk of bleeding. If there are any signs or symptoms suggesting bleeding, such as abnormal bleeding, easy bruising, blood in urine or stool, headache, confusion, slurred speech, or changes in vision, seek medical attention immediately.

2. Allergic reaction: Before taking the medicine, the patient should be asked whether he has received defibrin treatment before, and the patient should be informed of the risk of allergic reaction, including anaphylaxis. If allergic symptoms occur, he should seek medical treatment immediately.

Summary

Defibrotide can be used as an option to treat hepatic veno-occlusive disease, but it cannot completely cure the disease. However, after active treatment, it can control the disease as much as possible and improve the patient's quality of life.

Recommended related articles: